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Intercellular Skin Barrier Lipid Composition and
Organization in Netherton Syndrome Patients
Jeroen van Smeden1,7, Michelle Janssens1,7, Walter A. Boiten1, Vincent van Drongelen1,2, Laetitia Furio3,4,5,
Rob J. Vreeken6, Alain Hovnanian3,4,5 and Joke A. Bouwstra1
Netherton syndrome (NTS) is a rare genetic skin disease caused by mutations in the serine protease inhibitor
Kazal-type 5 gene, which encodes the lympho-epithelial Kazal-type–related inhibitor. NTS patients have
profoundly impaired skin barrier function. As stratum corneum (SC) lipids have a crucial role in the skin barrier
function, we investigated the SC lipid composition and organization in NTS patients. We studied the SC
lipid composition by means of mass spectrometry, and the lipid organization was examined by infrared
spectroscopy and X-ray diffraction. Decreased free fatty acid (FFA) chain length and increased levels of
monounsaturated FFAs were observed in the SC of NTS patients compared with controls. Furthermore, the
level of short-chain ceramides (CERs) was enhanced in NTS patients and a strong reduction in long-chain CER
levels was seen in several patients. The changes in lipid composition modified the lipid organization leading to an
increased disordering of the lipids compared with the controls. In addition, in a subgroup of patients the
organization of the lipid layers changed dramatically. The altered FFA and CER profiles in NTS patients
corresponded to changes in the expression of enzymes involved in SC lipid processing. The observed changes
in lipid composition, lipid organization, and enzyme expression are likely to contribute to the barrier dysfunction
in NTS.
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INTRODUCTION
Netherton syndrome (NTS) is a rare skin disorder with an
occurrence of 1–3 in 200,000 births and a fatality rate of
B20% in the first year of life (Hausser et al., 1989; Smith
et al., 1995; Pruszkowski et al., 2000; Bitoun et al., 2002; Sun
and Linden, 2006). NTS is characterized by erythroderma, a
specific hair shaft defect (bamboo hair) and severe atopic
manifestations (Greene and Muller, 1985). In addition, NTS
patients show a drastically reduced skin barrier function
(Fartasch et al., 1999; Moskowitz et al., 2004; Hachem
et al., 2006). The skin barrier is primarily located in the
outermost layer of the skin, the stratum corneum (SC). The SC
consists of flattened corneocytes embedded in a highly
ordered lipid matrix. The organization and composition of
this lipid matrix is thought to be crucial for the barrier function
of the skin but hardly any information is available on the SC
lipids regarding NTS patients. The aim of the present study is
therefore to unravel the composition and organization of this
SC lipid matrix in NTS.
SC lipids mainly consist of ceramides (CERs), cholesterol,
and free fatty acids (FFAs). To date, 12 CER subclasses have
been identified in human SC. Each CER subclass has a wide
distribution of total number of carbon atoms, ranging between
32 and 56 except for the very long acyl-CERs (62–78 carbon
atoms). A more detailed explanation is provided in Supple-
mentary Text online and Supplementary Figure S1 online
(Masukawa et al., 2009; van Smeden et al., 2011). FFAs
mainly consist of saturated carbon chains with lengths varying
between 16 and 36 carbon atoms, of which the most abundant
chain lengths are 24 and 26 carbon atoms (Norlen et al.,
1998; Ponec et al., 2001). In healthy SC, lipids form two
lamellar phases with repeat distances of B6 and 13 nm
referred to as the short periodicity phase and long periodicity
phase (LPP), respectively (Bouwstra et al., 1991). Within
the lamellae the lipids form a dense (orthorhombic, highly
ordered lipid chains) organization, although a less dense
(hexagonal, less-ordered lipid chains) lipid organization also
coexist (Pilgram et al., 1999) illustrated in Supplementary
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Figure S2 online. The lipid properties are crucial for a proper
SC barrier function, and several studies have shown the
importance of the SC lipids in atopic eczema (AE) patients
(Imokawa et al., 1991; Di Nardo et al., 1998; Ishikawa et al.,
2010; Janssens et al., 2012), a multifactorial skin disease that
shares symptoms with NTS (Krol and Krafchik, 2006; Elias,
2010).
NTS is caused by mutations in the serine protease inhibitor
Kazal-type 5 (SPINK5) gene. These mutations result in loss of
function of lympho-epithelial Kazal-type–related inhibitor
(Chavanas et al., 2000) leading to increased activity of
several kallikrein-related peptidases, thereby affecting various
biological processes that have a detrimental effect on the skin
barrier (Fartasch et al., 1992; Hachem et al., 2005; Deraison
et al., 2007; Bonnart et al., 2010).
In addition, NTS patients show different expression of
terminal differentiation markers such as loricrin, involucrin,
and transglutaminases, which disturbs the assembly of the
cornified envelope surrounding the corneocytes (Raghunath
et al., 2004; Hitomi, 2005; Di et al., 2009). Altogether, this
results in a drastically reduced barrier function in patients
with NTS as measured by transepidermal water loss (TEWL)
(Fartasch et al., 1999; Moskowitz et al., 2004; Hachem et al.,
2006).
Little is known about the SC lipid composition in NTS. A
study by Bonnart et al. (2010) with transgenic mice
overexpressing elastase 2 reported a 3-fold increase in TEWL
demonstrating a reduced skin barrier function. In addition, the
lipids in total epidermis were analyzed. Increased levels
of glucosylceramides (GlcCERs) together with a reduction of
sphingomyelin and FFA levels were observed. In addition,
irregular loose stacks of lamellae were described (Hausser and
Anton-Lamprecht, 1996; Fartasch et al., 1999; Bonnart et al.,
2010). However, no data have been reported on CER and FFA
subclasses and the distribution of total number of carbons of
each of the lipid classes and subclasses. In addition, no
quantitative information about the lamellar phases and
lateral packing has been reported. Therefore, the aim of this
study was to perform an in depth analysis of the lipid
composition and organization in SC of patients with NTS. In
addition, the levels of acyl-GlcCERs (precursors of acyl-CERs)
and the expression of several enzymes involved in SC lipid
processing were examined.
RESULTS
Decreased FFA chain length and increased degree of
unsaturation in SC of patients with NTS
In NTS patients there is a lower level of saturated FFAs com-
pared with SC of controls (71.3±24.1% and 97.0±1.1%,
respectively) and consequently a higher level of monounsatu-
rated fatty acids (MUFAs) compared with controls
(28.7±24.1% and 3.0±1.1%, respectively). Individual sub-
ject data are listed in Supplementary Figure S3a online.
Figure 1a shows the distribution of total number of carbons
of saturated FFAs in NTS patients (black) and in controls (gray).
We report relative values (%) because the main focus is the
relation between lipid composition and lipid organization,
and the lipid organization only depends on the relative
abundances of lipid subclasses and not on absolute amounts.
However, the supplement includes absolute data on FFAs
(Supplementary Figure S4 online), CERs, and GlcCERs. The
most abundant chain lengths in controls are C24:0 and C26:0.
Compared with control subjects, FFAs in NTS patients show a
shift to shorter chain length: there is a trend for increase in FFA
C20:0 and C21:0 and a decrease in FFAs C24:0, C25:0, and
C26:0. Figure 1b shows the distribution of total number of
carbons of MUFAs. In contrast to controls, NTS patients show
a significant level of MUFAs C20:1, C22:1, C24:1. From the
abundance of both the saturated FFAs and MUFAs, the
average chain length for each patient and control was calcu-
lated. The average FFA chain length is significantly reduced in
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Figure 1. Relative chain length distribution of stratum corneum (SC) free fatty
acids (FFAs). (a, b) Present bar graphs showing the relative abundance of,
respectively, saturated FFAs and monounsaturated fatty acids (MUFAs). The
total abundance of saturated FFAs and MUFAs together was set to 100%.
Controls (n¼ 5) and Netherton syndrome (NTS) patients (n¼ 8) are presented
as gray and black bars, respectively. Error bars represent SD values; ND means
‘not detected’. No odd chain length MUFAs were detected from either NTS or
controls. The large SD of the NTS patients are caused by intersubject variation
and are not due to methodological variation.
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NTS patients versus controls, being 23.4±0.9 and 24.5±0.1
carbon atoms, respectively (Supplementary Figure S3b online).
Altered levels of acyl-CERs, short-chain CERs, and acyl-GlcCERs
in SC of NTS patients
Representative examples of CER profiles of controls and NTS
patients are presented in the three-dimensional (3D) ion
chromatograms in Figure 2; the remaining subjects is provided
in Supplementary Figure S5 online. For absolute data on the
CERs, we refer to Supplementary Figure S6 online, which
illustrates that the total amount of CERs is reduced in NTS
(including the acyl-CERs), whereas the amounts of short-chain
CERs is increased. Figure 2a shows a representative example
of the CER profile of a control. Twelve CER subclasses are
identified, as reported before (van Smeden et al., 2011).
Within each CER subclass each peak indicates CER species
with a different chain length, and all 12 CER subclasses show
a wide distribution in their total number of carbons. CERs with
higher mass values in the upper part of the 3D mass spectrum
belong to the CER [EO] subclasses (noted as acyl-CERs) and
show a distribution of total number of carbons between 63
and 78 carbon atoms. The a-hydroxy [A] and non-hydroxy [N]
CER subclasses have shorter chains and therefore lower
masses. The carbon chain lengths of these subclasses are
between 34–52 and 32–56 carbon atoms, respectively. The
3D ion chromatograms of NTS patients are provided in
Figure 2b and c. Of all CER subclasses, CER [NP] was most
significantly reduced in NTS patients, whereas CER subclasses
[AS], [NS], and [AH] were least affected. Furthermore, there is
a shift in the distribution of total number of carbons in the
lipids of all NTS patients to lower mass values compared with
controls: increased peak intensities in the molecular range
between 550 and 650 a.m.u. are observed in chromato-
grams of NTS patients, corresponding to a total chain length
of B34–40 carbon atoms. In particular, CERs with a chain
length of 34 carbon atoms are increased. The ion chromato-
gram of Figure 2 represents five NTS patients (A, E, F, 7 , and
8 ). All CER subclasses are observed in these patients. There is
a clear shift to a higher abundance of short-chain CERs,
particularly the C34 CERs of subclasses [NS], [AS], and [AH].
In NTS subject F, these changes are most pronounced.
Figure 2c shows the ion chromatogram representative for the
remaining three NTS patients (B,C and D). These patients
show a clearly distinguishable pattern from the other five NTS
patients: There is a narrow distribution of total number of
carbons in [A] and [N] subclasses and the level of acyl-CERs is
drastically decreased, whereas the C34 CERs are strongly
increased.
The relative abundance of acyl-CERs and short-chain CERs
are shown in Figure 3a and b, respectively. Controls show
on average a relative abundance of 8.4±1.9% acyl-CERs
(absolute data in Supplementary Figure S6b online). This
abundance was comparable for five out of eight NTS patients,
but three patients show a drastic reduction to B2.5%. All
patients show a higher abundance of very short-chain CERs
with a mass lower than 600 a.m.u. (corresponding to a total
chain length of t38 carbon atoms) compared with control
subjects (27.2±6.0% and 8.5±1.3%, respectively).
Close examination of the mass spectra led to the identifica-
tion of CERs with a MUFA chain. These lipid species observed
in all CER subclasses were identified by their exact mass and
retention time, and were recently observed in cultured
human skin (Thakoersing et al., 2013). This is illustrated in
Supplementary Figure S7 online for CER [NP]. No unsaturated
CERs were observed in control subjects, whereas multiple
unsaturated CERs of different chain length and subclasses were
observed in NTS patients. NTS subject F does show the
highest abundance of unsaturated lipids (CERs and FFAs).
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Figure 2. Three-dimensional (3D) ion chromatograms showing all stratum corneum (SC) ceramide (CER) subclasses and chain lengths. (a) Control SC and (b, c)
Netherton syndrome (NTS) patients. Retention time (3.6–8.3 min), mass (480–1200 a.m.u.), and relative intensity of each peak are shown on the x, y, and z axis,
respectively. Chromatograms are normalized to their most abundant peak. The chromatograms of the NTS patients show a decreased chain length of the CERs. In
addition, in c there is a decrease in acyl-CERs ([EO] CERs) and a narrower distribution of total number of carbons in all other CER subclasses. NTS patients also
show an increase in short-chain CERs, in particular CERs with a chain length of 34 carbon atoms (C34 CERs), which are indicated in the chromatograms by red
peaks. The 3D ion chromatograms of all controls and NTS patients are listed in Supplementary Figure S5 online.
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As the CER profiles are changed in NTS patient, we also
studied the CER precursors in these patients. We primarily
focused on the precursors of the acyl-CERs, (the acyl-GlcCERs,
Supplementary Figure S8 online) because these CERs were
drastically decreased in some patients. Compared with controls,
the amount of acyl-CERs is reduced but the acyl-GlcCERs
remain unchanged in NTS patients (respectively, Supplemen-
tary Figures S6b and S9b online). This resulted in a significant
increase in the ratio acyl-GlcCERs/acyl-CERs in NTS patients
(Figure 3c), whereas the non-acyl-GlcCERs/CERs (excluding
acyl-GlcCERs and acyl-CERs) are not changed (not shown).
Altered lamellar lipid organization in NTS
Figure 4a–d show diffraction patterns of controls and NTS
patients. The positions of the peaks are indicative for the
periodicity (d) of the lipid lamellae: a shift to higher q-values
indicate a shorter d. All controls show clear peaks at q-values
of 1.00±0.01 and 1.45±0.01 nm 1. The 1.00-nm 1 diffrac-
tion peak is attributed to the second-order peak of the LPP and
the first-order peak of the short periodicity phase, whereas the
1.45-nm1 peak is attributed to the third order of the LPP. In
addition, some controls also show the first order of the LPP as
a weak shoulder at a q-value located at B0.50 nm1. These
peaks can be attributed to the two lamellar phases with repeat
distances of around 13 (LPP) and 6 nm (short periodicity
phase). Figure 4b and c show diffraction patterns of NTS
patients. Small angle X-ray diffraction patterns of NTS patients
(numbers A, E, F, 7 , and 8 ) who clearly showed acyl-CERs
present in their 3D ion chromatograms are depicted in
Figure 4b. The presence of a diffraction peak at 0.5 nm1,
but also the presence of peak ‘2’ and ‘3’ in patients A, E, 7 ,
and 8 suggests that the LPP is present. The diffraction pattern
of patient 8 is very similar to that of the controls, although the
peak position indicated by ‘2’ is shifted to slightly higher q-
values suggesting a reduction in the repeat distances of the
lamellar phases. In the small angle X-ray diffraction pattern of
SC from patients A,E, and 7 the peak indicated as ‘3’ has a
higher intensity compared with that in the controls and shifted
to either lower or higher q-values. The most likely explanation
is the formation of additional phases. The diffraction pattern of
patient F does not show any diffraction peak. Figure 4c shows
the small angle X-ray diffraction curves of the NTS patients
(numbers B, C, and D) who have a low level of acyl-CERs
present in the 3D ion chromatograms in Figure 2. No peaks
are observed in the diffraction patterns of these NTS patients
indicating the absence of regularly stacked lipid layers.
Higher degree of disordering of the lipid chains in NTS
Figure 5 shows the CH2 symmetric stretching peak position of
the SC lipids in controls (gray) and NTS patients (black),
assessed by Fourier transform infrared spectroscopy. A higher
peak position indicates a higher degree of disordering of the
lipid chains. The average peak position of the NTS patients
(2,850.0±0.6 cm 1) is higher compared with controls
(2,849.4±0.1 cm 1). In addition, a larger variability between
NTS patients compared with controls was observed when
performing a nonparametric Levene’s test (Po0.05).
Altered expression of SC lipid enzymes
Figure 6 shows the expression of enzymes involved in SC lipid
synthesis in two NTS patients and a control. (Supplementary
Figure S10 online shows two additional subjects and
Supplementary Figure S11 online shows the hematoxylin/
eosin/safranin staining, both illustrating the epidermal
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Figure 3. Relative abundance of specific ceramides (CERs). Dot plots showing
the relative abundance of (a) CERs, (b) short-chain CERs (C32-C38), and (c) the
ratio of acyl-glucosylceramides (GlcCERs)/acyl-CERs. Black horizontal lines
and the corresponding values indicate mean values (±SD). Gray dotted lines
indicate averages for two different cohorts observed: five Netherton syndrome
(NTS) patients with normal acyl-CER levels and three NTS patients with
reduced acyl-CER levels. Individual NTS patients are labeled A– 8 .
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hyperplasia in NTS patients (acanthosis)). Stearoyl-CoA desa-
turase-1 (involved in converting FFAs into MUFAs) shows
primarily expression in the stratum basale and stratum spino-
sum in control skin, but in NTS skin the expression is
moderately detected in all epidermal layers.
With respect to elongase (ELOVL)-1 and 6 (responsible for
elongation of the FFAs), the epidermis of NTS patients shows
a much lower expression of these enzymes compared with
control epidermis, which is primarily expressed in (outer
layers of) the stratum granulosum. The expression of the CER
synthesis-related enzymes b-glucocerebrosidase (GBA) and
acid sphingomyelinase (aSMase) was also examined. Expres-
sion of these enzymes in control skin is mainly located at the
interface between the stratum granulosum and the lower
layers of the SC. In contrast, expression of GBA in NTS
epidermis is much less localized and more diffuse. The
expression of aSMase was different among the NTS patients:
two patients demonstrate an almost complete absence of
aSMase in their epidermis (NTS E and F), whereas the other
two show expression in all epidermal layers but with reduced
expression in the SC (e.g., NTS, 7 , and 8 ).
DISCUSSION
Both the lipid composition and organization in SC of NTS
patients deviates largely from that in controls. The reduced
amounts of both FFAs and CERs indicate that the total lipid
amount should also be reduced. Indeed, Supplementary
Figure S12 online shows that the weight percentage of the
lipids is reduced in NTS patients, although values are highly
deviating (controls: 24.4±5.1%, NTS 12.2±9.3). More pre-
cisely, there is a relative increase in short-chain FFAs levels in
SC of NTS patients. In addition, the amounts of MUFAs are
drastically increased in NTS patients. Similar changes were
observed in the CER composition: increased levels of unsatu-
rated CERs and short-chain CERs in SC of NTS patients,
whereas the total amount of CERs is decreased.
We also observed a higher degree in disordering of the lipid
chains as well as an altered lamellar organization in SC of NTS
patients. These changes in lipid organization did not correlate
with the total lipid amount (R2¼0.17), indicating that other
factors are important for the higher degree of disordering, like
the composition of the lipids. Indeed, the changes in the lipid
Control NTS - [EO] CERs present NTS - [EO] CERs reduced
10 3
Ar
bi
tra
ry
 in
te
ns
ity
Ar
bi
tra
ry
 in
te
ns
ity
Ar
bi
tra
ry
 in
te
ns
ity
3
2
2
2
2
3
3
3
3
3
2
1
1
1
3
2
2
2
2 3
3
1
1
1
1
q (nm–1) q (nm–1) q (nm–1)
d
≈13 nm
2 4 10 32 4
1
8
5
7
6
4
3
2
10 32 4
Figure 4. Small angle X-ray diffraction (SAXD) patterns. (a) Controls and (b, c) Netherton syndrome (NTS) patients. The positions of the peaks (q) are indicative for
the periodicity of the lipid lamellae (illustrated by the inset in the upper right corner of a. Panel b shows NTS patients with a normal level of acyl-ceramides
(CERs), whereas panel c presents diffraction patterns of NTS patients with a reduced level of acyl-CERs. From the scattering angle, the scattering vector
(q) was calculated by q¼ 4p siny/l, in which l is the wavelength of the X-rays at the sample position and y is the scattering angle. Individual NTS patients
are labeled A– 8 .
Stretching peak position
Control NTS
2,848
2,849
2,850
2,851
2,852
St
re
tc
hi
ng
 p
ea
k 
po
sit
io
n 
(cm
–
1 )
*
2,849.4 ± 0.1
2,850.0 ± 0.6 /
/6 4
5
71
3
2
8
Figure 5. CH2 symmetric stretching peak position in stratum corneum (SC) of
controls (gray dots) and Netherton syndrome (NTS) patients (black dots).
A higher peak position indicates a higher degree of conformational disordering
of the lipid chains. Individual NTS patients are labeled A– 8 .
J van Smeden et al.
Stratum Corneum Lipids in Netherton Patients
1242 Journal of Investigative Dermatology (2014), Volume 134
composition correlated to changes in the lipid organization;
NTS patients with normal levels of acyl-CERs in their SC (A, E,
7 , and 8 ) revealed a diffraction pattern indicating the
presence of the LPP. In contrast, NTS patients with low levels
of acyl-CERs (B, C, and D) did not show any proper SC
lamellar organization. The exception is NTS patient F. Despite
a high level of acyl-CERs present in the SC, no proper lamellar
phases were detected. However, this patient shows the highest
level of short-chain CERs and unsaturated CERs. In addition,
the highest level of MUFAs and the shortest average FFA chain
length were observed. The abundant presence of shorter and
unsaturated chains enhances disordering of the lipid organiza-
tion and may therefore explain the lack of regularly stacked
lipid lamellae (Groen et al., 2011). Only one patient ( 8 )
showed a diffraction profile very similar to the controls. This
patient exhibits the least deviation in SC lipid composition
compared with the control subjects.
It has been reported that NTS patients show a drastic
reduction in skin barrier function, as indicated by increased
TEWL values (Fartasch et al., 1999; Moskowitz et al., 2004;
Hachem et al., 2006). As the lipids have a crucial role in the
skin barrier function, an altered lipid composition and thus a
change in lipid organization may contribute to the increased
TEWL values in NTS patients. In previous studies using model
lipid systems, we observed that in the absence of acyl-CERs a
drastic reduction in LPP was observed, whereas an increased
level in short-chain FFAs and/or MUFAs result in a reduced
presence of the orthorhombic packing (Bouwstra et al., 1996,
2001). These changes in lipid organization result in an
increase in permeability (de Jager et al., 2006; Groen et al.,
2011). Recently, Eckl et al. (2013) demonstrated the
importance of acyl chain length of CERs for the barrier
function in autosomal recessive congenital ichthyosis. As far
as the GlcCERs are concerned, the levels observed in NTS do
not significantly affect the lateral packing (Gooris et al.,
unpublished data at the Leiden University, 2013).
NTS is an inflammatory disease that shares skin barrier
defects and allergic features with AE (Krol and Krafchik, 2006;
Elias, 2010). In particular, NTS patients display ‘‘eczema-like’’
lesions and numerous allergic manifestations with high IgE
levels. We therefore provide a brief comparison in lipid
profiling between this study on NTS patients and a study in
AE patients we performed recently for which we examined
identical parameters. Concerning the lipid composition,
several changes observed in NTS have also been reported in
the SC of patients with AE. These changes are (i) a reduction in
the level of acyl-CERs; (ii) increased levels of CER [AS] and
CER [NS] and a reduced level of CER [NP]; (iii) increased
levels in C34 CERs; (iv) a shift to shorter chain lengths in FFAs
and CERs; and (v) increased levels in MUFAs. Compared with
control subjects, changes in these lipid parameters are already
observed at non-lesional skin sites of AE subjects. These
changes become much more pronounced at lesional AE skin
sites and in NTS patients. Supplementary Table S1 online
provides more quantitative data on this matter. Also, with
respect to the lamellar and lateral organization of the lipids,
we observe similarities. Both in patients with AE and NTS, we
observed a reduction in repeating distance of the lipid
lamellae. In addition, the peak of the CH2 stretching vibrations
in the Fourier transform infrared spectroscopy spectrum are
shifted to higher values, indicative for a less-ordered lipid
organization. Identical to the lipid composition, these changes
are most pronounced in NTS patients.
In AE, these changes in lipid composition and the subse-
quent altered lipid organization correlated very well with an
increased TEWL (Ishikawa et al., 2010; Janssens et al., 2012;
van Smeden et al., 2013). Therefore, these changes in lipid
composition and organization may also contribute to the
impaired skin barrier in NTS. In AE we observed that
changes in the SC lipids were more pronounced in lesional
skin compared with non-lesional skin, which may indicate
that either inflammation and/or the presence of surface
bacteria may have a role in changes in the lipid composition.
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The underlying causes of altered FFA and CER composition
in NTS is likely to be related to an altered epidermal lipid
processing. Downregulation of ELOVL-1, 4, and 6 has been
shown to associate with a reduced CER chain length in a
murine model of AE (Park et al., 2012), demonstrating that
these enzymes may be involved in the reduction of CER chain
length. In addition, mice lacking functional ELOVL-1 show a
strong reduction in long-chain CERs (especially 4C26; Sassa
et al., 2013). We therefore studied the expression of ELOVL-1
and 6 and demonstrate differences between NTS patients and
controls. Reduced expression of ELOVL-1 is in line with
reduced amounts of FFAs4C24 observed in NTS. As
ELOVL-6 converts FFA C16 into FFA C18, a reduced
expression of ELOVL-6 would result in more C16 FFAs and
therefore may contribute to the increased levels in C34 CERs
as the sphingoid base is usuallyB18 carbon atoms. Moreover,
we observed that stearoyl-CoA desaturase-1 is expressed
throughout the entire viable epidermis in NTS patients,
implying that the conversion from saturated FFAs to MUFAs
occurs in all viable epidermal layers in NTS. This is in line
with the increased abundance of MUFAs observed here.
We also report drastic changes in specific CER subclasses
profile in NTS patients. This can be explained by changes in
the enzymes GBA and aSMase, responsible for conversion of
CER precursors into their specific CER subclasses. The altered
expression of these enzymes near the stratum granulosum/SC
interface indicates an impaired conversion from CER precur-
sors into CERs. For GBA (the enzyme that converts GlcCERs
into CERs), this is in agreement to our observed increase in
ratio of acyl-GlcCERs (acyl-CER precursors) in NTS patients.
Although the reason(s) underlying the alterations in the
enzymatic pathways of the SC barrier lipids remain(s) to be
elucidated, elastase 2 hyperactivity and lower natural moist-
urizing factor levels due to SPINK5 mutations are likely to
result in increased pH in the SC of NTS patients This may lead
to alterations in SC CER subclass levels in NTS as the activity
of aSMase and GBA are both highly dependent on the pH in
their microenvironment (Hachem et al., 2003, 2005; Mauro
et al., 2006). Furthermore, a pH increase induces high serine
proteases activity that in turn degrades lipid-processing
enzymes (Hachem et al., 2005). Upregulation of kallikrein
activity has also been reported to affect enzymes involved in
lipid synthesis. Finally, the bound SC lipids (Farwanah et al.,
2007) may be important for the intercellular lipid formation
and skin barrier function (Meguro et al., 2000), and could
therefore contribute to defective skin barrier in NTS.
In conclusion, this study shows that the SC lipid composi-
tion and organization are both altered in NTS patients, which
is in agreement with the expression of enzymes related to the
synthesis of SC FFAs and CERs being altered. These anomalies
in SC lipids show similarities with those in AE and are likely to
contribute to the skin barrier dysfunction in NTS.
MATERIALS AND METHODS
General information on the Materials and Methods is listed below.
Additional information on some of the detailed methodological
procedures is located in the supplement. The study was conducted
in accordance with the Declaration of Helsinki, approved by the
Ethical Committee of Toulouse, and written informed patient consent
was obtained. Eight patients with classical features of NTS (details in
Supplementary Table S2 online) were included in the study and
compared with SC of five controls. SC obtained from NTS patients
were of comparable regions as those of controls (i.e., abdomen or
breast). In addition, biopsies were taken from four NTS patients to
obtain full thickness skin used for (immuno)histochemical staining.
Primary antibodies ELOVL-1 and 6 were obtained from Santa Cruz
Biotechnology (Santa Cruz, CA), stearoyl-CoA desaturase-1 from
Sigma-Aldrich (Zwijndrecht, the Netherlands), and GBA and aSMase
from Abcam (Cambridge, MA). The secondary antibodies used were
rhodamine Goat anti-rabbit and Cy3 Goat anti-mouse (Jackson
ImmunoResearch Laboratories, (West Grove, PA)). Lipids from SC
sheets were collected by liquid/liquid extraction (Bligh and Dyer,
1959) before analysis by liquid chromatography/mass spectrometry
(van Smeden et al., 2011, 2014). The lamellar and lateral lipid
organization were studied by small angle X-ray diffraction and Fourier
transform infrared spectroscopy, respectively (Bras et al., 2003;
Janssens et al., 2012).
Statistical analysis
Statistical analysis was performed using SPSS Statistics. Nonpara-
metric Mann–Whitney tests were performed when comparing two
groups, unless explicitly noted elsewhere. Differences were consid-
ered either trending toward significance (Po0.1), moderately sig-
nificant (Po0.05), or highly significant (Po0.005) and are denoted
throughout the manuscript as *, **, and ***, respectively.
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